Document is current
Any future updates will be listed below
-
Authors
Birge, R B
Boeltz, S https://orcid.org/0000-0001-5227-8707
Kumar, S
Carlson, J
Wanderley, J https://orcid.org/0000-0002-9707-6284
Calianese, D
Barcinski, M
Brekken, R A
Huang, X
Hutchins, J T
Freimark, B
Empig, C
Mercer, J
Schroit, A J
Schett, G
Herrmann, M
- License Information
-
More Information
Article History
Received: 31 October 2015
Revised: 5 January 2016
Accepted: 7 January 2016
First Online: 26 February 2016
Competing interests
: JC, JTH, BF, and CE are paid employees of Peregrine Pharmaceuticals. RAB receives funding from and is a consultant for Peregrine Pharmaceuticals. MH wants to disclose the involvement in Patent Application EP1356818 A3 filed at the European Patent Office in 1995 and entitled ‘Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria, and parasites’. This patent application has already expired. Peregrine Pharmaceuticals, Inc., is the owner or exclusive licensee of hundreds of unexpired worldwide patents broadly covering compositions that target PS and various methods of use, including to treat cancer and viral infections. The remaining authors declare no conflict of interests.
